Anesthesia with ciprofol in cardiac surgery with cardiopulmonary bypass: A case report

Abstract

BACKGROUND

Ciprofol is a novel agent for intravenous general anesthesia. In February 2022, it was approved by the National Medical Products Administration for general anesthesia induction and maintenance. It has the advantages of fast onset, fast elimination, stable circulation, and few adverse reactions. However, the efficacy and safety of ciprofol in cardiac surgery with cardiopulmonary bypass have not been reported. Here we describe a case where ciprofol was successfully used for anesthesia in cardiac surgery with cardiopulmonary bypass.

CASE SUMMARY

A 72-year-old man (height 176 cm; weight 70 kg) was diagnosed with coronary atherosclerotic cardiomyopathy requiring coronary artery bypass grafting and left ventricular aneurysmectomy. Ciprofol was administered for induction (0.4 mg/kg) and maintenance (0.6-1.0 mg/kg/h) of general anesthesia. During the entire operation, the bispectral index, hemodynamics, and blood oxygen saturation were maintained at normal levels. The patient recovered well after surgery, with no serious adverse events related to ciprofol.

CONCLUSION

Ciprofol is safe and effective for anesthesia in cardiac surgery with cardiopulmonary bypass.

Keywords: Ciprofol; Coronary artery bypass grafting; Left ventricular aneurysmectomy; Cardiopulmonary bypass; Case report

Core Tip: Ciprofol is a novel agent for intravenous general anesthesia. It is characterized by fast onset, fast elimination, stable circulation, and few adverse reactions. This is the first case report of ciprofol administration for anesthesia in cardiac surgery with cardiopulmonary bypass. Based on our experience in this case, we conclude that ciprofol is safe and effective for anesthesia in cardiac surgery with cardiopulmonary bypass. With further testing, ciprofol may replace propofol in the field of anesthesia for cardiac surgeries.